Developer docs
API playgroundTry for free, no card

Search company profiles

Sekisui Diagnostics

Full company profile

uuid0009qq7

Namestring
Sekisui Diagnostics
Legal namestring
Sekisui Diagnostics, LLC
Company typeenum
Private
Founded yearint
1980
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical chemistry reagents, point-of-care diagnostics, molecular diagnostic tests, diagnostic enzymes, pre-analytic systems
Industry4 codes
1IVD Reagents, Assay Kits & Consumables (Non-instrument)
CodeHLAHAAAMPrimaryYes
2Genetic, Cytogenetic & Prenatal Screening IVD
CodeHLAHAAAIPrimaryNo
3Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
CodeHLAHAAALPrimaryNo
4Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
CodeHLAHAAANPrimaryNo
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers423450
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Clinical Chemistry Reagents Sales
TypeOne Time License
Description

Sale of clinical chemistry reagents including SEKURE® reagents, calibrators, controls, and linearity materials. Products are used to perform over 1.8 billion clinical chemistry tests each year on various branded clinical chemistry analyzers. Revenue generated through direct sales and distributor networks.

sekisuidiagnostics.com
2Point-of-Care Testing Products
TypeOne Time License
Description

Sale of rapid diagnostic tests (OSOM® brand) and molecular testing products (Metrix® platform) for point-of-care settings including physician offices, clinics, and hospitals. Products detect various conditions including respiratory infections, women's health issues, and infectious diseases.

sekisuidiagnostics.com
3Enzyme Manufacturing
TypeOne Time License
Description

Manufacturing and sale of high-quality enzymes and specialty biochemicals to global healthcare market. Enzymes are used in pharmaceutical production, clinical chemistry reagents, and POC/biosensor devices. Products include clinical chemistry enzymes, pharmaceutical antibiotic production enzymes, biosensors, molecular enzymes, and immunodiagnostics enzymes.

sekisuidiagnostics.com
4Pre-Analytic Systems
TypeOne Time License
Description

Supply of raw materials for blood collection tube manufacturers including serum separation gel and blood clotting accelerant. These materials ensure reliable diagnostic results in plastic vacuum blood collection tubes.

sekisuidiagnostics.com
5Contract Development and Manufacturing Services (CDMO)
TypeProfessional Services
Description

End-to-end manufacturing services for liquid and lyophilized products from design to full-scale commercialization. Services include formulation, design, development, filling, QC testing, packaging & labeling. Located in Prince Edward Island, Canada with global logistics capabilities.

sekisuidiagnostics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Direct Sales Contact
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing determined by several factors. Contact sales team for detailed product information. Regional contact numbers available for Americas (800-332-1042) and EMEA/APAC regions.

sekisuidiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1OSOM®
Description

Brand for rapid diagnostic tests including COVID-19, Flu, RSV, Strep A, Trichomonas, BVBLUE, Mono, H. pylori, and hCG tests.

sekisuidiagnostics.com
+6 more records
Core offering1 text field

Sekisui Diagnostics develops, manufactures, and supplies in vitro diagnostic (IVD) products including clinical chemistry reagents, rapid point-of-care tests (OSOM), molecular diagnostic platforms (Metrix), diagnostic and pharmaceutical enzymes, and pre-analytic raw materials (serum separation gel, blood clotting accelerant) for blood collection tubes. The company also offers end-to-end contract development and manufacturing (CDMO) services for liquid and lyophilized products to global healthcare customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 1.8 billion clinical chemistry tests performed annually using SEKISUI products
+2 more records
Product overview1 text field

Sekisui Diagnostics offers a diversified portfolio of diagnostic products organized into five main categories: Clinical Chemistry (reagents, calibrators, controls, and the STAT-Site WB meter for glucose/ketone testing), Point-of-Care Testing (OSOM rapid tests for respiratory, women's health, and infectious disease applications, plus the Metrix molecular platform for COVID/Flu testing), Enzymes (clinical chemistry enzymes, pharmaceutical antibiotic production enzymes, biosensor enzymes, molecular enzymes for PCR, and immunodiagnostics), Pre-Analytic Systems (blood collection tube raw materials including serum separation gel and clotting accelerants), and Contract Manufacturing Services (CDMO for liquid/lyophilized products). The company operates manufacturing facilities in Canada, UK, and US, serving healthcare professionals, distributors, and manufacturers globally.

Product and service16 records
1Clinical Chemistry Reagents
CategoryClinical Chemistry
Description

Broad line of 65+ reagents including cardiovascular, diabetes, renal, liver, therapeutic drug, and specialty assays used on automated clinical chemistry analyzers by hospital and reference laboratories.

2SEKURE Clinical Chemistry Reagents
CategoryClinical Chemistry
Description

Ready-to-use liquid stable open-channel clinical chemistry reagents designed to help laboratories meet operational and financial goals with exceptional performance and field-proven reliability.

3Calibrators, Controls & Linearity Materials
CategoryClinical Chemistry
Description

Range of calibrators, controls, and linearity materials for commonly performed clinical chemistry tests to improve laboratory analytical performance, including DC-Lineate tri-level calibration material.

4STAT-Site WB Meter
CategoryPoint-of-Care Testing
Description

CLIA waived point-of-care meter for beta-ketone and glucose measurements from whole blood with results in less than 10 seconds, intended for clinical point-of-care settings.

5Bulk Reagents
CategoryClinical Chemistry
Description

Clinical chemistry reagents manufactured in bulk for instrument manufacturers (OEM), including assays for Acetaminophen, Albumin, ALP, ALT, Ammonia, Amylase, AST, Calcium, Cholesterol, CO2, Creatine Kinase, Creatinine, CRP, and others.

6Clinical Chemistry Enzymes
CategoryEnzymes
Description

Diagnostic enzymes for clinical chemistry applications including cholesterol oxidase, glucose dehydrogenase, CNPG3, and valinomycin for diabetes, lipid metabolism, renal function, and cardiovascular testing.

7Pharmaceutical Antibiotic Production Enzymes
CategoryEnzymes
Description

Enzymes for efficient inactivation of beta-lactam antibiotics including penicillins, cephalosporins, and carbapenems for environmental and quality control testing in antibiotic manufacturing.

8Biosensor Enzymes
CategoryEnzymes
Description

Enzymes for biosensor applications focused on determination of D-glucose in clinical analysis and self-monitoring blood glucose meters, including glucose oxidase and glucose dehydrogenase.

9Molecular Enzymes
CategoryEnzymes
Description

Enzymes for PCR applications including KOD DNA polymerases, reverse transcriptase, Taq DNA polymerase, and realtime PCR master mix for infectious disease and oncology testing.

10Immunodiagnostics Enzymes and Reagents
CategoryEnzymes
Description

Detection and labeling materials for immunoassay applications including streptavidin, SAV magnetic beads, alkaline phosphatase, horseradish peroxidase, and Smartbond Streptavidin for chemiluminescent signal detection.

11OSOM Rapid Tests
CategoryPoint-of-Care Testing
Description

Broad range of rapid point-of-care lateral flow diagnostic tests including COVID-19, RSV, Flu SARS-CoV-2 Combo, BVBLUE, H. pylori, iFOB, Mono, Strep A, Trichomonas, Ultra hCG Combo, and Ultra Plus Flu A&B tests for physician offices and clinics.

12Metrix COVID/Flu Test
CategoryPoint-of-Care Testing
Description

Highly accurate molecular multiplex test that detects and differentiates between SARS-CoV-2, Flu A, and Flu B at the point-of-care with results in 20 minutes and minimal hands-on time; no calibration or maintenance required.

13Metrix COVID-19 Test
CategoryPoint-of-Care Testing
Description

Molecular test for qualitative detection of SARS-CoV-2 nucleic acids accommodating both nasal or saliva samples, delivering lab-quality results in 30 minutes or less on the Metrix platform.

14Serum Separation Gel
CategoryPre-Analytic Systems
Description

Raw material for plastic vacuum blood collection tubes allowing stable and reliable separation of blood clot and serum with high resistance to irradiation, sold to blood collection tube manufacturers.

15Blood Clotting Accelerant
CategoryPre-Analytic Systems
Description

Raw material for blood collection tubes ensuring reliable diagnostic results through accelerated blood clot formation, supplied to blood collection tube manufacturers.

16Contract Development and Manufacturing Services (CDMO)
CategoryContract Manufacturing Services
Description

End-to-end contract manufacturing services for liquid and lyophilized products from design to full-scale commercialization, including formulation, filling, QC testing, packaging, and labeling, operated from the Prince Edward Island, Canada facility with ISO 8 cleanrooms and lyophilization capacity.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Microbix Biosystems Inc. partnered with SEKISUI Diagnostics to support U.S. commercialization of COVID/Flu molecular test. Microbix supplies REDxFLOQ QAPs (Quality Assessment Products) that help ensure test accuracy and compliance. The test, authorized under FDA Emergency Use Authorization, detects SARS-CoV-2, Influenza A, and Influenza B within 20 minutes using the Metrix® platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SEKISUI Diagnostics partnered with Aptitude to provide Metrix COVID-19 tests to the point-of-care and home test markets. This partnership expands distribution of the Metrix molecular testing platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

QuidelOrtho (formerly Quidel + Ortho Clinical Diagnostics) develops immunoassays, clinical chemistry reagents, and rapid point-of-care diagnostics — directly comparable to Sekisui's clinical chemistry reagent plus OSOM rapid-test portfolio.

TypeDirect peer
Description

Bio-Rad manufactures clinical chemistry controls, calibrators, quality-control materials and diagnostic reagents — a direct peer to Sekisui's SEKURE reagents and calibrators/controls/linearity line.

TypeDirect peer
Description

OraSure develops rapid point-of-care diagnostics (infectious disease, women's health) and is a comparable peer to Sekisui's OSOM rapid-test franchise and home-test positioning.

TypeDirect peer
Description

Trinity Biotech manufactures clinical chemistry and diagnostic tests for point-of-care and laboratory use — comparable in scale, scope, and customer base to Sekisui's clinical chemistry and POC business.

TypeDirect peer
Description

EKF Diagnostics produces point-of-care analyzers, clinical chemistry reagents, and OEM enzymes/biochemicals — closely comparable to Sekisui across POC, clinical chemistry, and enzyme product lines.

TypeDirect peer
Description

Meridian develops and manufactures diagnostic test kits and reagents for infectious disease, gastrointestinal, and respiratory testing — comparable to Sekisui's OSOM and Metrix franchises.

TypeDirect peer
Description

Response Biomedical develops rapid point-of-care immunoassay tests (cardiovascular, infectious disease) — a similar mid-cap POC diagnostic peer in scope and distribution.

TypeBroad incumbent
Description

Hologic is a larger, diversified diagnostics company with molecular and rapid-test capabilities — overlapping Sekisui's molecular Metrix platform but operating at significantly broader scale.

TypeBroad incumbent
Description

Beckman Coulter is a major clinical chemistry and immunoassay analyzer/reagent incumbent that competes with Sekisui's SEKURE open-channel reagents on the same analyzer platforms.

TypeBroad incumbent
Description

Roche Diagnostics is the global IVD leader across clinical chemistry, immunoassays, and molecular — the dominant incumbent against which Sekisui's specialty POC and enzyme businesses compete for share.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sekisui Diagnostics

In Vitro Diagnosticssekisuidiagnostics.com

Sekisui Diagnostics firmographics

Firmographics
Name
Sekisui Diagnostics
Legal name
Sekisui Diagnostics, LLC
Website
https://sekisuidiagnostics.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Sekisui Diagnostics industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
akta.pro secondary industries
Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

  • Clinical chemistry reagents
  • Point-of-care diagnostics
  • Molecular diagnostic tests
  • Diagnostic enzymes
  • Pre-analytic systems

Where Sekisui Diagnostics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Sekisui Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Chemistry Reagents Sales: Sale of clinical chemistry reagents including SEKURE® reagents, calibrators, controls, and linearity materials. Products are used to perform over 1.8 billion clinical chemistry tests each year on various branded clinical chemistry analyzers. Revenue generated through direct sales and distributor networks.
  2. Point-of-Care Testing Products: Sale of rapid diagnostic tests (OSOM® brand) and molecular testing products (Metrix® platform) for point-of-care settings including physician offices, clinics, and hospitals. Products detect various conditions including respiratory infections, women's health issues, and infectious diseases.
  3. Enzyme Manufacturing: Manufacturing and sale of high-quality enzymes and specialty biochemicals to global healthcare market. Enzymes are used in pharmaceutical production, clinical chemistry reagents, and POC/biosensor devices. Products include clinical chemistry enzymes, pharmaceutical antibiotic production enzymes, biosensors, molecular enzymes, and immunodiagnostics enzymes.
  4. Pre-Analytic Systems: Supply of raw materials for blood collection tube manufacturers including serum separation gel and blood clotting accelerant. These materials ensure reliable diagnostic results in plastic vacuum blood collection tubes.
  5. Contract Development and Manufacturing Services (CDMO): End-to-end manufacturing services for liquid and lyophilized products from design to full-scale commercialization. Services include formulation, design, development, filling, QC testing, packaging & labeling. Located in Prince Edward Island, Canada with global logistics capabilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDirect Sales Contact

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Sekisui Diagnostics product offering

Product offering

Core offering

Sekisui Diagnostics develops, manufactures, and supplies in vitro diagnostic (IVD) products including clinical chemistry reagents, rapid point-of-care tests (OSOM), molecular diagnostic platforms (Metrix), diagnostic and pharmaceutical enzymes, and pre-analytic raw materials (serum separation gel, blood clotting accelerant) for blood collection tubes. The company also offers end-to-end contract development and manufacturing (CDMO) services for liquid and lyophilized products to global healthcare customers.

Product overview

Sekisui Diagnostics offers a diversified portfolio of diagnostic products organized into five main categories: Clinical Chemistry (reagents, calibrators, controls, and the STAT-Site WB meter for glucose/ketone testing), Point-of-Care Testing (OSOM rapid tests for respiratory, women's health, and infectious disease applications, plus the Metrix molecular platform for COVID/Flu testing), Enzymes (clinical chemistry enzymes, pharmaceutical antibiotic production enzymes, biosensor enzymes, molecular enzymes for PCR, and immunodiagnostics), Pre-Analytic Systems (blood collection tube raw materials including serum separation gel and clotting accelerants), and Contract Manufacturing Services (CDMO for liquid/lyophilized products). The company operates manufacturing facilities in Canada, UK, and US, serving healthcare professionals, distributors, and manufacturers globally.

Differentiator

Problem solved

Functional benefit

Brands

  • OSOM®: Brand for rapid diagnostic tests including COVID-19, Flu, RSV, Strep A, Trichomonas, BVBLUE, Mono, H. pylori, and hCG tests.
  • SEKURE®
  • Metrix®
  • STAT-Site®
  • QC Inside®
  • DC-Lineate
  • Smartbond Streptavidin

Products and services

  • Clinical Chemistry Reagents Broad line of 65+ reagents including cardiovascular, diabetes, renal, liver, therapeutic drug, and specialty assays used on automated clinical chemistry analyzers by hospital and reference laboratories.
  • SEKURE Clinical Chemistry Reagents Ready-to-use liquid stable open-channel clinical chemistry reagents designed to help laboratories meet operational and financial goals with exceptional performance and field-proven reliability.
  • Calibrators, Controls & Linearity Materials Range of calibrators, controls, and linearity materials for commonly performed clinical chemistry tests to improve laboratory analytical performance, including DC-Lineate tri-level calibration material.
  • STAT-Site WB Meter CLIA waived point-of-care meter for beta-ketone and glucose measurements from whole blood with results in less than 10 seconds, intended for clinical point-of-care settings.
  • Bulk Reagents Clinical chemistry reagents manufactured in bulk for instrument manufacturers (OEM), including assays for Acetaminophen, Albumin, ALP, ALT, Ammonia, Amylase, AST, Calcium, Cholesterol, CO2, Creatine Kinase, Creatinine, CRP, and others.
  • Clinical Chemistry Enzymes Diagnostic enzymes for clinical chemistry applications including cholesterol oxidase, glucose dehydrogenase, CNPG3, and valinomycin for diabetes, lipid metabolism, renal function, and cardiovascular testing.
  • Pharmaceutical Antibiotic Production Enzymes Enzymes for efficient inactivation of beta-lactam antibiotics including penicillins, cephalosporins, and carbapenems for environmental and quality control testing in antibiotic manufacturing.
  • Biosensor Enzymes Enzymes for biosensor applications focused on determination of D-glucose in clinical analysis and self-monitoring blood glucose meters, including glucose oxidase and glucose dehydrogenase.
  • Molecular Enzymes Enzymes for PCR applications including KOD DNA polymerases, reverse transcriptase, Taq DNA polymerase, and realtime PCR master mix for infectious disease and oncology testing.
  • Immunodiagnostics Enzymes and Reagents Detection and labeling materials for immunoassay applications including streptavidin, SAV magnetic beads, alkaline phosphatase, horseradish peroxidase, and Smartbond Streptavidin for chemiluminescent signal detection.
  • OSOM Rapid Tests Broad range of rapid point-of-care lateral flow diagnostic tests including COVID-19, RSV, Flu SARS-CoV-2 Combo, BVBLUE, H. pylori, iFOB, Mono, Strep A, Trichomonas, Ultra hCG Combo, and Ultra Plus Flu A&B tests for physician offices and clinics.
  • Metrix COVID/Flu Test Highly accurate molecular multiplex test that detects and differentiates between SARS-CoV-2, Flu A, and Flu B at the point-of-care with results in 20 minutes and minimal hands-on time; no calibration or maintenance required.
  • Metrix COVID-19 Test Molecular test for qualitative detection of SARS-CoV-2 nucleic acids accommodating both nasal or saliva samples, delivering lab-quality results in 30 minutes or less on the Metrix platform.
  • Serum Separation Gel Raw material for plastic vacuum blood collection tubes allowing stable and reliable separation of blood clot and serum with high resistance to irradiation, sold to blood collection tube manufacturers.
  • Blood Clotting Accelerant Raw material for blood collection tubes ensuring reliable diagnostic results through accelerated blood clot formation, supplied to blood collection tube manufacturers.
  • Contract Development and Manufacturing Services (CDMO) End-to-end contract manufacturing services for liquid and lyophilized products from design to full-scale commercialization, including formulation, filling, QC testing, packaging, and labeling, operated from the Prince Edward Island, Canada facility with ISO 8 cleanrooms and lyophilization capacity.

Quantifiable outcome

  • Over 1.8 billion clinical chemistry tests performed annually using SEKISUI products
  • +2 more outcomes

Companies that use Sekisui Diagnostics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Sekisui Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Sekisui Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Microbix Biosystems Inc.coreStrategic or Co-development Partner · 12 November 2025Microbix Biosystems Inc. partnered with SEKISUI Diagnostics to support U.S. commercialization of COVID/Flu molecular test. Microbix supplies REDxFLOQ QAPs (Quality Assessment Products) that help ensure test accuracy and compliance. The test, authorized under FDA Emergency Use Authorization, detects SARS-CoV-2, Influenza A, and Influenza B within 20 minutes using the Metrix® platform.
  • Aptitude Medical SystemscoreStrategic or Co-development PartnerSEKISUI Diagnostics partnered with Aptitude to provide Metrix COVID-19 tests to the point-of-care and home test markets. This partnership expands distribution of the Metrix molecular testing platform.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Sekisui Diagnostics competitors and assessment

Company assessment

Direct peers

  • QuidelOrtho: QuidelOrtho (formerly Quidel + Ortho Clinical Diagnostics) develops immunoassays, clinical chemistry reagents, and rapid point-of-care diagnostics — directly comparable to Sekisui's clinical chemistry reagent plus OSOM rapid-test portfolio.
  • Bio-Rad Laboratories: Bio-Rad manufactures clinical chemistry controls, calibrators, quality-control materials and diagnostic reagents — a direct peer to Sekisui's SEKURE reagents and calibrators/controls/linearity line.
  • OraSure Technologies: OraSure develops rapid point-of-care diagnostics (infectious disease, women's health) and is a comparable peer to Sekisui's OSOM rapid-test franchise and home-test positioning.
  • Trinity Biotech: Trinity Biotech manufactures clinical chemistry and diagnostic tests for point-of-care and laboratory use — comparable in scale, scope, and customer base to Sekisui's clinical chemistry and POC business.
  • EKF Diagnostics: EKF Diagnostics produces point-of-care analyzers, clinical chemistry reagents, and OEM enzymes/biochemicals — closely comparable to Sekisui across POC, clinical chemistry, and enzyme product lines.
  • Meridian Bioscience: Meridian develops and manufactures diagnostic test kits and reagents for infectious disease, gastrointestinal, and respiratory testing — comparable to Sekisui's OSOM and Metrix franchises.
  • Response Biomedical: Response Biomedical develops rapid point-of-care immunoassay tests (cardiovascular, infectious disease) — a similar mid-cap POC diagnostic peer in scope and distribution.

Broad incumbents

  • Hologic: Hologic is a larger, diversified diagnostics company with molecular and rapid-test capabilities — overlapping Sekisui's molecular Metrix platform but operating at significantly broader scale.
  • Beckman Coulter (Danaher): Beckman Coulter is a major clinical chemistry and immunoassay analyzer/reagent incumbent that competes with Sekisui's SEKURE open-channel reagents on the same analyzer platforms.
  • Roche Diagnostics: Roche Diagnostics is the global IVD leader across clinical chemistry, immunoassays, and molecular — the dominant incumbent against which Sekisui's specialty POC and enzyme businesses compete for share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sekisui Diagnostics social profiles

Digital presence

Sekisui Diagnostics compliance and trust

Trust signal

Compliance9 records

Sekisui Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sekisui Diagnostics leadership team

Management profile

Number of profiles

Profiles10 records

Sekisui Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Sekisui Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sekisui Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sekisui Diagnostics

What does Sekisui Diagnostics do?

Sekisui Diagnostics develops, manufactures, and supplies in vitro diagnostic (IVD) products including clinical chemistry reagents, rapid point-of-care tests (OSOM), molecular diagnostic platforms (Metrix), diagnostic and pharmaceutical enzymes, and pre-analytic raw materials (serum separation gel, blood clotting accelerant) for blood collection tubes. The company also offers end-to-end contract development and manufacturing (CDMO) services for liquid and lyophilized products to global healthcare customers.

Is Sekisui Diagnostics a public or private company?

Sekisui Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was Sekisui Diagnostics founded?

Sekisui Diagnostics was founded in 1980. It employs 501 to 1,000 people.

Where is Sekisui Diagnostics based?

Sekisui Diagnostics is headquartered in Lexington, United States, in the North America region.

How does Sekisui Diagnostics make money?

Five revenue lines are on record. Clinical Chemistry Reagents Sales are the primary driver. The others are point-of-Care Testing Products, enzyme Manufacturing, pre-Analytic Systems and contract Development and Manufacturing Services (CDMO).

Who are Sekisui Diagnostics's main competitors?

Direct peers on record are QuidelOrtho, Bio-Rad Laboratories, OraSure Technologies, Trinity Biotech, EKF Diagnostics, Meridian Bioscience and Response Biomedical. Broad incumbents are Hologic, Beckman Coulter (Danaher) and Roche Diagnostics.

Does Sekisui Diagnostics have an API?

No public API is recorded for Sekisui Diagnostics.

What industry is Sekisui Diagnostics in?

Sekisui Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Patient Care OnlineFDA Authorizes Aptitude Metrix COVID/Flu Multiplex Molecular Test for Home and Point-of-Care UseAptitude Medical Systems, Inc. received Emergency Use Authorization from the US FDA for its Metrix COVID/Flu multiplex molecular diagnostic test, enabling over-the-counter use in home and point-of-care settings. The test detects SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes, aiming to provide a more accurate and cost-effective alternative to traditional antigen tests for urgent care providers. Aptitude stated that the test is available nationwide through its distribution partners, including Sekisui Diagnostics.openPR.comSegmentation, Major Trends, and Competitive Overview of the Rapid Diagnostics MarketThe global rapid diagnostics market is projected to reach $64.79 billion by 2030, growing at a compound annual growth rate of 12.4%, driven by investments in molecular diagnostics, connected diagnostic devices, and home-based testing solutions. In June 2023, UK-based biotechnology firm Avacta Group acquired Belgium's Coris Bioconcept SRL to broaden its rapid testing capabilities in infectious diseases and antimicrobial resistance. In May 2025, US-based SEKISUI Diagnostics launched the OSOM RSV Test, a rapid diagnostic tool that delivers results in 15 minutes for respiratory syncytial virus detection.Clinical Lab ProductsMicrobix Partners with Sekisui Diagnostics for COVID/Flu Test Quality ControlsMicrobix Biosystems has partnered with Sekisui Diagnostics to provide quality assessment products for the US commercialization of the Metrix COVID/Flu Test developed by Aptitude Medical Systems. The collaboration involves Microbix supplying REDx FLOQ Quality Assessment Products to support operator training and ensure compliance for the molecular point-of-care assay. This initiative aims to facilitate the widespread adoption of the test, which holds Emergency Use Authorization from the FDA.openPR.comPoint-of-Care Testing Devices Market is projected to reach USD 101.51 billion by 2033 | Siemens Healthcare, Danaher Corporation, SEKISUI Diagnostics, Trinity Biotech, Beckman Coulter Inc, Nova BiomediThe global point-of-care testing devices market was valued at $49.73 billion in 2024 and is projected to reach $101.51 billion by 2033, a CAGR of 8.6%. Technological advancements and new FDA approvals, such as Masimo's MightySat Medical, are driving growth.SekisuidiagnosticsSEKISUI Diagnostics Announces Launch of the OSOM® RSV TestSEKISUI Diagnostics has launched the OSOM® RSV Test, a rapid diagnostic tool for detecting Respiratory Syncytial Virus (RSV) in healthcare settings, effective from May 21, 2025. The test provides results in just 15 minutes and is designed for use in high-risk patient groups, including children and seniors. This new product aims to enhance diagnostic accuracy and improve patient care amidst overlapping symptoms of respiratory infections.PR NewswireSEKISUI Diagnostics Announces Launch of the OSOM® RSV TestSEKISUI Diagnostics launched the OSOM RSV test, a rapid immunochromatographic assay for detecting RSV nucleoprotein antigen in nasal swabs. The CLIA-waived test delivers results in 15 minutes and targets children 6 months to 6 years and adults 60 and older. It includes a QC Inside feature providing two extra tests per kit.GlobeNewswireNorth America Leads Specialty Enzymes Market Amid Rising Demand for Diagnostics and TherapeuticsThe global specialty enzymes market is projected to grow from $6.1 billion in 2024 to $9.2 billion by 2029, a CAGR of 8.5%. Growth is driven by biotechnology advancements, healthcare investment, and North America's leading position. Key developments include New England Biolabs' enzyme kit and Sekisui Diagnostics' expansion.SekisuidiagnosticsHarnessing Artificial Intelligence for Healthcare: A Future Ready ApproachA blog post outlines how artificial intelligence can be integrated into healthcare diagnostics, covering machine learning and deep learning applications in imaging, genomics, bio-signals and laboratory medicine. It cites benefits such as improved prediction accuracy, speed and workflow automation, alongside ethical concerns around patient autonomy, transparency and accessibility. The author, representing SEKISUI, notes its 2021 partnership with Avasure on Telesitter Solutions and a proof concept with Hitachi.PR NewswireHealthcare Specialty Enzymes Global Market Opportunities And Strategies To 2031Reportlinker published a market research report titled 'Healthcare Specialty Enzymes Global Market Opportunities And Strategies To 2031,' which analyzes the global healthcare specialty enzymes market across multiple regions and segments. The report covers market characteristics, size, growth projections (2016–2031), competitive landscape, and strategic recommendations for industry participants. Key companies mentioned in the report scope include F. Hoffmann-La Roche AG, Merck Millipore, Thermo Fisher Scientific Inc., Codexis Inc., and Sekisui Diagnostics.BiotechCanada @ BIO 2025At BIO 2025 in Boston, Canada showcased its biotechnology ecosystem with close to 500 Canadian companies participating over four days, highlighting the sector's innovations and collaboration. A significant announcement during the event was SEKISUI Diagnostics' $16 million investment to expand manufacturing capabilities in Prince Edward Island, aiming to enhance its production capacity for global clients. The gathering emphasized Canada's leadership in advancing important biotechnology solutions, including radiopharmaceuticals.